Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Iowa to track meth precursors

This article was originally published in The Tan Sheet

Executive Summary

Gov. Chet Culver (D) signs a law establishing a real-time electronic repository to monitor sales of ephedrine- and pseudoephedrine-containing products in Iowa. Senate File 237, enacted March 25 and effective July 1, makes Iowa the seventh state to mandate electronic logbooks for purchases of nonprescription methamphetamine precursors, according to the National Association of Chain Drug Stores. Oklahoma, Arkansas, Kentucky and West Virginia actively track PSE sales. Hawaii and Missouri have approved but have yet to implement systems. The Kansas Senate has approved an electronic logbook bill (1"The Tan Sheet" March 16, 2009, In Brief)

You may also be interested in...



Illinois pilot program tracks PSE

Six Illinois counties begin electronically tracking pharmacy purchases of nonprescription products containing pseudoephedrine June 15 as part of a pilot program overseen by the Southern Illinois Enforcement Group. The Illinois State Police Precursor Tracking Program is slated for evaluation after eight months to determine the feasibility of a statewide system for monitoring purchases of methamphetamine precursors. Tom McNamara, special projects coordinator for Carbondale-based SIEG, said in an interview the e-tracking system is online but will not be fully operational until Aug. 17. In March, Iowa became the seventh state to mandate electronic tracking for purchases of meth ingredients (1"The Tan Sheet" April 6, 2009, In Brief)

Kan. Senate votes for meth precursor e-tracking

A statewide system for tracking purchases of nonprescription products containing ephedrine or pseudoephedrine is a step closer to reality after the Kansas Senate passes S.B. 248. Following its March 12 approval by 37-3 margin, the bill will next be considered in the state House. Other states have set up similar electronic logbooks to monitor purchases of methamphetamine precursors - including Tennessee, which says its statewide tracking system has been a success (1"The Tan Sheet" Feb. 2, 2009, p. 4). ... Mo. Senate votes down PSE Rx amendment: An attempt to amend a larger crime bill with a measure requiring a prescription for products containing methamphetamine precursors fails in the Missouri state Senate March 4. The amendment offered by state Sen. Jason Crowell, a Republican representing the Cape Girardeau area, "was soundly defeated" by voice vote, according to a legislature spokesman. Separately, Crowell has sponsored a bill, S.B. 160, to make cough/cold remedies containing ephedrine or pseudoephedrine available by prescription only, which remains viable (2"The Tan Sheet" Feb. 23, 2009, p. 3). A companion bill, H.B. 496, is under consideration in the House and has been passed out of committee

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

Topics

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel